The use of levofloxacin in a patient with leptospirosis

References (5)

1. Shalit I, Barnea A, Shahar A: Efficacy of ciprofloxacin againts interrogans serogroup icterohaemorrhagiae. Antimicrob Agents Chemother. 33: 788-789, 1989. Leptospira Sünbül M: Leptospiroz. ANKEM Derg. 20 (Ek2): 219-221, 2006.
2. Bharti AR, Nally JE, Ricaldi JN, Matthias MA, Diaz MM, Lovett MA, Levett PN, Gilman RH, Willig MR, Gotuzzo E, Vinetz JM: Leptospirosis: a zoonotic disease of globalimportance. Lancet Infect Dis. 3: 757–771, 2003. http://www.med.monash.edu.au/microbiol ogy/staff/adler/leptoguidelines2003pdf Takashima I, Ngoma M, Hashimoto N: Antimicrobial effects of a new carboxyquinolone drug, Q-35, on five serogroups of Leptospira interrogans. Antimicrob Agents Chemother. 37: 901- 902, 1993.
3. Truccola J, Charavay F, Merien F, Perolat P: Quantitative PCR assay to evaluate ampicillin, ofloxacin, and doxycycline for treatment of experimental leptospirosis. Antimicrob Agents Chemother. 46: 848- 852, 2002. Schonberg A: Studies on the effect of antibiotic substances on leptospires and their cultivation from material with a high bacterial count. Zentralbl Bacteriol A. 249: 400-406, 1981.
4. Sugunan AP, Natarajaseenivasan K, Vijayachari P, Seghal SC: Percutaneous exposure resulting in laboratory-acquired leptospirosis -a case report. J Med Microbiol. 53: 1258-1262, 2004.
5. Mancel E, Merrien F, Pesenti L, Salino D, Angibaud G, Perolat P: Clinical aspects of ocular leptospirosis in New Caledonia (South Pacific). Aust N Z J Ophthalmol. 27: 380– 386, 1999. National Committee for Clinical Laboratory Standards: dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa,1997.